Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06968481 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 1, 2026 to Oct 30, 2026v2 Show 5 more changesShow less
    • Start date: Oct 1, 2025 to May 30, 2026
    • Study completion date: Apr 30, 2026 to Oct 30, 2026
    • Interventions: Oxytocin (Drug), Oxytocin (Drug) to Oxytocin IM (Drug), Oxytocin sublingual (Drug)
    • Study description expanded, about 54 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open-label, randomized, single-center, dose ascending trial will be conducted to evaluate the efficacy and safety of sublingual oxytocin for the prevention of post-partum hemorrhage caused by uterine atony in term pregnant women having an uncomplicated vaginal delivery.
Trial Details
NCT Number NCT06968481
Lead Sponsor Insud Pharma
Conditions
(from sponsor)		 Post Partum Hemorrhage
Related terms Postpartum Hemorrhage
Enrollment 330 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov